To compare longitudinal changes in weight, body fat, and ratio of central to peripheral fat mass among first-time depot-medroxyprogesterone acetate (DMPA) users to women using no hormonal contraception, and to evaluate user characteristics associated with that change. DESIGN: Prospective longitudinal study. SUBJECTS: Healthy women, aged 18-35 y, using DMPA for contraception (n ¼ 178) and women using no hormonal contraception (n ¼ 145). MEASUREMENTS: Weight, body fat, and the central distribution of fat, measured at 3-month intervals for 30 months, by electronic scale and dual-energy X-ray absorptiometry (DEXA). The ratio of central to peripheral distribution of body fat was computed by dividing the body fat in the conventional DEXA trunk region of interest (ROI) by the ROI's that encompass the arms, hips and legs. RESULTS: Women using DMPA had a significantly greater increase in all measures of fatness than women using no hormonal method of contraception (Po0. In contrast, weight, fat mass and the ratio of central to peripheral fat mass of control participants remained virtually unchanged over the same time period. Women with higher baseline physical activity levels had a smaller increase in body fat (P ¼ 0.003) and the fat ratio (P ¼ 0.03), but not weight (P ¼ 0.48). No other user characteristics including, smoking, past oral contraceptive use or previous pregnancies predicted change in level of fatness. CONCLUSIONS: This study has demonstrated a change in body composition toward greater fatness and toward a central redistribution of fat among DMPA users as compared to controls and provides important information to be used when counseling women regarding contraceptive methods. Given the potential long-term implication of these changes, further study is recommended to determine whether the gains in fatness are reversed following DMPA discontinuation and to examine the role of progestins in the development and maintenance of obesity.
Introduction
Obesity and overweight are becoming the most important public health problems in the United States. More than 60% of the adult US population is now overweight or obese, and obesity is developing at increasingly younger ages. 1 Furthermore, evidence suggests that overweight children and adolescents remain overweight or become obese as adults. 2 The causes of overweight and obesity are multifactorial; however, one potential contributor to weight gain in adolescents and young adult women is their choice of hormonal contraception. Depot-medroxyprogesterone acetate (DMPA) is a progestin-only injectable contraceptive administered every 11-13 weeks; it is used by approximately 11% of women choosing hormonal contraception. 3 Weight gain is a commonly reported side effect and is cited second only to irregular bleeding as the primary reason for DMPA discontinuation. [4] [5] [6] Published studies of weight changes among DMPA users are inconsistent. Some studies report no weight changes unique to DMPA users [7] [8] [9] [10] while others find average weight gains as high as 9 kg in 2 y or less. 6, [11] [12] [13] [14] Most of these studies have used either retrospective designs or did not include controls in the prospective design. Thus, it is difficult to discern if the weight changes, or lack thereof, are due to the potential weight-related dropout bias in the retrospective studies, or to the failure to discriminate DMPA-related weight gain from usual weight gain in uncontrolled prospective studies. The only prospective, controlled study of DMPA-related weight gain reported no change in weight between the DMPA and the control group. However, in that study the sample size was limited to 11 DMPA users and controls who were followed for a single, 3-month DMPA injection period. 9 None of these published studies has included measures of fat mass or its distribution. DMPA-related increases in weight or fat mass during late adolescence and young adulthood, if substantial, may increase the future risk of obesity. Understanding the magnitude of weight and other body composition changes among DMPA users is important in order to better appreciate that risk. Accordingly, the purpose of this study was to longitudinally characterize the 30-month changes in measures of fatness (weight, fat mass, and the ratio of central to peripheral fat) in a large number of women using either DMPA or no hormonal contraception.
Methods
Body composition was measured as part of a prospective longitudinal study evaluating bone mineral density (BMD) changes among women, aged 18-35 y, with and without DMPA use. 15 The study enrolled 323 women over 18 months beginning April 2000, including 178 women who newly initiated DMPA 150 mg for contraception and 145 control participants who used no hormonal contraception. Participants were recruited from family planning and gynecology clinics, newspaper advertisements, dormitories, residence halls, workplaces, local business establishments, and by word-of-mouth. Potential enrollees were excluded if they did not meet the age requirement; had fewer than nine menstrual cycles per year; were pregnant or breastfeeding in the 6-month period prior to study baseline; reported a history of infertility, seizure disorder, thyroid disease, autoimmune diseases, diabetes, or eating disorders; were regularly (more than two times per week) using oral or inhaled steroid medication; or had ever used DMPA or Norplant. The University of Iowa's Institutional Review Board approved the study and all enrollees gave informed consent prior to participation and received monetary compensation for their participation. Study participants were evaluated at 3-month intervals for up to 30 months. DMPA users completed the baseline visit within 1 week of the initial injection. Subsequent visits were scheduled to correspond with DMPA injections, which averaged 84 days apart. Control participants were evaluated between day 1 and day 7 of the follicular phase of their menstrual cycles and their average visit interval was 93 days. As a result of the difference in average visit intervals, over the 30-month observation period the maximum number of possible visits for DMPA users was 12, while the maximum number for controls was 11 visits.
A total of 139 (78.1%) of DMPA users and 114 (78.6%) control participants completed the entire 30 months of observation. Not all of those who completed the entire observation period maintained their contraceptive status. The DMPA discontinuation rate averaged 6.8% per visit during the first year and 6.4% per visit during the second year. Persistent vaginal bleeding, weight gain, and desire to become pregnant were the primary reasons for DMPA discontinuation. For controls, the hormonal contraceptive initiation rate averaged 6.3% per visit during the first year and 7.2% per visit during year 2. Measures of baseline fat mass, lean mass, and weight did not differ between those participants who remained in the study and maintained their original contraceptive status and those who either quit the study or changed contraceptive status (discontinued DMPA or began hormonal contraceptives). Data for all participants were included in the analyses until a participant either quit the study or changed contraceptive status, at which point data for that individual was censored. The analyses included data from 1277 visits for DMPA-users and 1027 visits for controls, and average of 7.2 visits per person for each of the groups. This provides a 90% power to detect yearly increases of 1.1 kg (4.5%) in fat mass, 1.5 kg (2.1%) in weight, and a 0.0154 change in fat ratio.
Measurements
Participants were weighed on an electronic scale (Tanita Corp, Arlington Heights, IL, USA) in light clothing without shoes. The scale precision was monitored daily by comparing the actual scale value to that of a standard 50 pound weight. Total fat and lean mass were measured with dual-energy X-ray absorptiometry (DEXA) (GE Lunar Prodigy,t Madison, WI). The precision of our body fat measures, determined by comparing same day, repeated measurement of body fat on 26 individuals taken by two different technicians, was 1.4%. The DEXA standard trunk region of interest (ROI) includes chest, abdomen, and pelvis and was used as an indicator of central obesity. The trunk ROI has a high correlation (r ¼ 0.77, Po0.001) with intra-abdominal adipose tissue, as measured by CT 16 and with visceral abdominal fat measured by MRI (r ¼ 0.825, Po0.01). 17 In order to determine whether there was a preferential deposition of fat in the central region, a ratio of central to peripheral distribution of body fat (fat ratio) was computed by dividing the body fat in the conventional DEXA trunk ROI by the combined fat mass in the ROI's that encompass the arms, hips, and legs. Quality assurance checks for the densitometer were performed daily using a calibration block consisting of tissue-equivalent material with three bone-simulating chambers. Mean baseline fat values of new enrollees was computed every 2 weeks and compared overtime to identify systematic changes in fat mass that may indicate machine drift. For this, trend analyses based on regression approaches were used to compute and evaluate the slope change over time; the slope remained within 0.2% over the entire 18-month enrollment period. Demographic, reproductive, medical, smoking, physical activity and alcohol consumption histories were obtained through structured interviews at baseline and updated at each follow-up visit. Average weekly physical activity for the between-visit interval was estimated through self-report of type, duration, and frequency of activity. Energy expenditure for each activity was converted to metabolic equivalent tasks (METs) as described by Ainsworth. 18 METs represent the energy expended during selected activities relative to that expended during rest. 18 
Statistical analyses
The characteristics of participants, at baseline, were described using means or medians for continuous variables (eg age, fat mass, and lean mass) and frequencies were calculated for categorical variables (eg prior oral contraceptive use, prior pregnancy, and smoking). Differences between the two groups, at baseline were evaluated using t-tests for normally distributed continuous variables and the Wilcoxon or w 2 test for non-normally distributed (physical activity) or categorical variables.
Plots were developed to describe the observed change in the measures of fatness over time. Longitudinal analyses of the repeated measurements of fatness were used to model change and to test its association with DMPA use. This was completed using the SAS Procedure Mixed. Models included DMPA-use as a main effect, as well as a time-by-contraceptive group interaction. This estimated the rate of change in measures of fatness in the DMPA group as compared to the non-DMPA group. Quadratic time terms were included in all models to determine the linearity of changes in body composition over time. Fixed covariates considered in the models included age at baseline, age at menarche, number of pregnancies, previous oral contraceptive use, and smoking status. Physical activity at each follow-up visit was included as a time-dependent covariate. The longitudinal analyses take into account the multiple observations over time and the within-person autocorrelation that occurs with these multiple observations. These analyses allow for variation in the number and spacing of observations across time that is inherent in longitudinal studies. 19 
Results
The population was predominantly white (n ¼ 278, 86. 1%) with 22 women (6.8%) designating themselves as black or African American, nine (2.7%) as Asian, six (1.9%) as American Indian, and eight (2.5%) as being of more than one race. The mean age was 22.1 y (s.d. ¼ 4.1). There were no significant differences between the DMPA users and controls in age or race/ethnicity.
As seen in Table 1 , DMPA users and nonusers were comparable with respect to weight, fat mass, lean mass, and ratio of central to peripheral fat mass at baseline. Likewise, at baseline, both groups were comparable with respect to self-reported cigarette smoking, physical activity, and age. DMPA users were significantly more likely to have Figures 1 and 2 . In all cases, the observed and modeled changes were very similar indicating robust modeled values. Women using DMPA had a significantly greater increase in all measures of fatness than women using no hormonal method of contraception (Po0.03). The observed weight of DMPA users increased steadily from a mean of 69.4 kg (s.d. ¼ 16.9) at baseline to a mean of 75.5 kg (s.d. ¼ 25.0) at 30 month; an increase of 6.1 kg (8.8.%), while the weight of controls remained virtually unchanged (Figure 1, upper  section) . Notably, the increase in weight observed with the DMPA users was solely related to an increase in fat mass. The amount of lean mass did not change over the 30 months for either the DMPA users or controls (Figure 1 Longitudinal models were used to identify characteristics that might influence the changes in weight, fat mass, and fat ratio ( Table 2 ). The length of time using DMPA (time*DMPA) was the best predictor of change in all measures of fatness (P ¼ o0.03) Women with greater physical activity levels had smaller increases in fat mass (P ¼ 0.003) and fat ratio (Po0.0001), but not weight (P ¼ 0.48). Women with larger central distribution of fat at baseline had greater increases in the fat ratio over 30 months (Po0.0001). No other characteristics, including baseline weight, baseline fat mass, prior oral contraceptive use, previous pregnancy or smoking, were significant predictors of change in weight, fat mass, or fat ratio.
Discussion
This is the first large, prospective study with a control comparison group to evaluate long-term weight change in women using DMPA for contraception. Furthermore, it is the only study to include measures of body composition and fat distribution. Our data demonstrate that, over 30 months, women using DMPA have a substantial increase in weight. This weight gain is comprised entirely of increased fat mass, not lean mass. These observations of significantly greater weight gain, increased fat mass, and increase in the central Fat and DMPA MK Clark et al deposition of fat among women using DMPA compared to controls demonstrate that changes in weight and fatness are unique to DMPA users and not just typical of all women, as some suggest. 20 Our observation that DMPA users had a significant increase in the central distribution of body fat has potential metabolic and vascular implications if not reversed following DMPA discontinuation. This central fat distribution pattern is a component of the metabolic syndrome and may predispose directly to the development of insulin resistance 21 and the generation of proinflamatory cytokines. 22 Visceral fat accumulation is an important determinant of plasminogen-activating inhibitor-1 (PAI-1) levels in young, nonobese men and women and contributes to vascular dysfunction. 23, 24 Although not studied extensively, there is evidence of decreased vascular function in women using DMPA for contraception. 25 The mechanism(s) by which DMPA could increase weight and fat mass while also altering fat distribution is unknown and cannot be discerned from our current study. However, the effects of DMPA or progesterone in humans and experimental animals raise interesting mechanistic possibilities. DMPA induces hypoestrogenemia 26 which has been linked to visceral fat accumulation and weight gain in both animal models 27, 28 and in humans. 29, 30 Alternatively, MPA can activate the glucocorticoid signaling receptor 31 and, in higher doses, has been associated with glucocorticoid-like changes in fat mass in humans, 32 which include increased visceral fat. 33 DMPA could also alter neurohumeral regulation of appetite and energy expenditure at the level of the hypothalamus as has been suggested in rodent models. 34 These mechanisms will need to be formally evaluated in other prospective studies. Our study demonstrates that higher levels of physical activity offered some protection against gains in fat mass and fat ratio, and this suggests a behavioral means of offsetting some of the DMPA-related increase in fat mass. It is not surprising that physical activity did not predict change in weight since physical activity is typically associated with increases in heavier lean mass. The role of physical activity in the prevention and treatment of obesity in general is well known. There is some evidence that physical activity reduces visceral fat mass in obese children and older men and women; 35, 36 however, the effect of activity on fat distribution has not been well studied. While this study compares longitudinal changes in body composition in a large cohort of young adult DMPA users and controls, there are limitations. This is not a clinical trial with random assignment to DMPA therapy. In addition, because the main focus of the study was on changes in BMD, Figure 2 Change in mean fat ratio over 30 months for women using DMPA for contraception (') and women using no hormonal method of contraception (J). Fat and DMPA MK Clark et al we did not collect biological or nutritional data that would help identify hormonal or appestatic mechanisms mediating the increase in weight and fat mass, or possible related metabolic consequences of the fat gain. Further study is needed to evaluate mechanisms for weight and fat gain and the metabolic consequences of that gain.
In any study of a contraceptive such as DMPA, it is important to balance the benefit of conception control with adverse events. Our study has demonstrated a major change in body composition to greater fatness and toward a central redistribution of fat among women using DMPA as compared to a control group. It is important to consider the magnitude of these changes in fatness when counseling women regarding contraceptive methods. Additionally, given the potential long-term implication of these changes, further study is needed to determine whether the gains in fatness are reversed following DMPA discontinuation and to examine the role of progestins in the development and maintenance of obesity. 
